How many drugs treat Bacterial conjunctivitis?

Drug Landscape tracks 10 marketed treatments for Bacterial conjunctivitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/bacterial-conjunctivitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Bacterial conjunctivitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bacterial conjunctivitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Bacterial conjunctivitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Besivance	BESIFLOXACIN	Bausch Health	Quinolone Antimicrobial [EPC]		2009-01-01
Zymar	GATIFLOXACIN	Allergan		DNA gyrase, DNA gyrase, DNA gyrase subunit A	2003-01-01
Avelox	moxifloxacin	Bayer AG	Fluoroquinolone antibiotic (fourth-generation)	DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A	1999-12-10
Levaquin	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2	1996-12-20
Zithromax	azithromycin	Pfizer Inc.	Macrolide antibiotic (azalide)	Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor	1991-11-01
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Vantobra	Tobramycin Sulfate	Pfizer	tobramycin	Taste receptor type 2 member 20	1974-01-01
Trimethoprim	TRIMETHOPRIM	Dr Reddys Labs Sa	Sulfonamide Antimicrobial [EPC]	Dihydrofolate reductase	1973-01-01
Gentamicin	Gentamicin Sulfate	Merck & Co.	gentamicin	Dihydrofolate reductase	1970-01-01
Garamycin	GENTAMICIN	Merck & Co.	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 5	1970-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 3 drugs in Bacterial conjunctivitis
· 3 drugs in Bacterial conjunctivitis
Merck & Co. · 2 drugs in Bacterial conjunctivitis
Bayer AG · 2 drugs in Bacterial conjunctivitis
Dr Reddys Labs Sa · 1 drug in Bacterial conjunctivitis
Generic (originally Daiichi Sankyo/J&J) · 1 drug in Bacterial conjunctivitis
Generic (originally Schering) · 1 drug in Bacterial conjunctivitis
Hannover Medical School · 1 drug in Bacterial conjunctivitis
Novartis · 1 drug in Bacterial conjunctivitis
Novartis Pharmaceuticals · 1 drug in Bacterial conjunctivitis
Ophthalmology Consultants, Ltd. · 1 drug in Bacterial conjunctivitis
Pfizer Inc. · 1 drug in Bacterial conjunctivitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Bacterial conjunctivitis:

Cite this brief

Drug Landscape (2026). Bacterial conjunctivitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/bacterial-conjunctivitis. Accessed 2026-06-10.

Bacterial conjunctivitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing